Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

This publication has 15 references indexed in Scilit:

• The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
  Blood, 2002
• Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient
  European Journal of Haematology, 2001
• Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2000
• Anticancer Derivative of Butyric Acid (Pivalyloxymethyl Butyrate) Specifically Potentiates the Cytotoxicity of Doxorubicin and Daunorubicin through the Suppression of Microsomal Glycosidic Activity
  Molecular Pharmacology, 2000
• Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units
  Investigational New Drugs, 1998
• An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells
  British Journal of Cancer, 1997
• Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL‐60 leukemic cell line
  International Journal of Cancer, 1994
• Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug
  FEBS Letters, 1993
• Novel anticancer prodrugs of butyric acid. 2
  Journal of Medicinal Chemistry, 1992
• Derivatives of butyric acid as potential anti‐neoplastic agents
  International Journal of Cancer, 1991